BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing patient-friendly compounds to treat neuro-psychiatric and neurological disorders.
Fulfilling our responsibility for healthy and sound minds
Burdens call for alternatives in the landscape of options ….
Societal strains, alarming & intensifying, ring for alternatives
Covid Mental Strain
Adult with Depression
Mental Health Spending
BetterLife Pharma’s lead product, 2-Bromo-LSD (BETR-001), is a second-generation lysergic acid diethylamide (“LSD”) derivative molecule that mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations. As a non-psychedelic, BETR-001 has the potential benefits without the hallucination related use restrictions and regulatory hurdles imposed on psychedelics.
Time-to-market solutions lean on key considerations
|CSA Schedule 1 Drug||No||Yes||Yes||Yes|
|Multiple Formal Human Studies||Yes||Yes||Yes||Yes|
|USDOJ List 1 Precursors||No||Yes||Yes||Yes|
|UN Convention Illicit Drug||No||Yes||Yes||Yes|
BETR-001 is a potential new therapy to treat debilitating psychiatric disorders with high unmet need, such as treatment-resistant depression and post-traumatic stress disorder; as well as severe neurological disorders such as cluster headaches. This compound represents a promising alternative to existing treatments but also compares favorably to other upcoming solutions.
BetterLife Pharma Inc. (BETR:CNX)
BetterLife Pharma Inc – Ordinary Shares (BETRF)